uz
Feedback
๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ

๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ

Kanalga Telegramโ€™da oโ€˜tish

ุจุณู… ุงู„ู„ู‡ ุงู„ุฑุญู…ู† ุงู„ุฑุญูŠู… ุงู„ู„ู‡ู… ุตู„ ุนู„ู‰ ู…ุญู…ุฏ ูˆุขู„ ู…ุญู…ุฏ ู…ุญุชูˆู‰ ุงู„ู‚ู†ุงุฉ: ุดุฑูˆุญุงุช ุตูŠุฏู„ุฉ ุนุถูˆูŠุฉ ู…ุฑุญู„ุฉ ุซุงู†ูŠุฉ ูƒูˆุฑุณ ุซุงู†ูŠ ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุซุงู„ุซุฉ ูƒูˆุฑุณ ุซุงู†ูŠ ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุฑุงุจุนุฉ ูƒูˆุฑุณ ุงูˆู„ ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุฑุงุจุนุฉ ูƒูˆุฑุณ ุซุงู†ูŠ ุนู„ุงุฌูŠุงุช ู…ุฑุญู„ุฉ ุฎุงู…ุณุฉ ู„ู„ุชูˆุงุตู„: @AronX2bot

Ko'proq ko'rsatish

๐Ÿ“ˆ Telegram kanali ๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ analitikasi

๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ (@aronstudy) Arab til segmentidagi kanali faol ishtirokchi. Hozirda hamjamiyat 13 339 obunachidan iborat bo'lib, Tibbiyot toifasida 1 928-o'rinni va Saudiya Arabistoni mintaqasida 5 694-o'rinni egallagan.

๐Ÿ“Š Auditoriya koโ€˜rsatkichlari va dinamika

ะฝะตะฒั–ะดะพะผะพ sanasidan buyon loyiha tez oโ€˜sib, 13 339 obunachiga ega boโ€˜ldi.

28 Iyun, 2026 dagi oxirgi maโ€™lumotlarga koโ€˜ra kanal barqaror faollikka ega. Oxirgi 30 kunda obunachilar soni 196 ga, soโ€˜nggi 24 soatda esa -18 ga oโ€˜zgardi va umumiy qamrov yuqori darajada qolmoqda.

  • Tasdiqlash holati: Tasdiqlanmagan
  • Jalb etish (ER): Auditoriya oโ€˜rtacha 27.91% darajada jalb etiladi. Nashrdan keyingi dastlabki 24 soatda kontent odatda umumiy obunachilar sonining 9.87% ini tashkil etuvchi reaksiyalarni toโ€˜playdi.
  • Post qamrovi: Har bir post oโ€˜rtacha 3 727 marta koโ€˜riladi; birinchi sutkada odatda 1 318 ta koโ€˜rish yigโ€˜iladi.
  • Reaksiyalar va oโ€˜zaro taโ€™sir: Auditoriya faol: har bir postga oโ€˜rtacha 36 ta reaksiya keladi.
  • Tematik yoโ€˜nalishlar: Kontent ู…ูŽุงุฏูŽู‘ุฉ, ุทูŽุงู„ูุจ, ุงูุณุชูุจููŠูŽุงู†, ุณูŽู„ูŽุงู…, ุฑูุณูŽุงู„ูŽุฉ kabi asosiy mavzularga jamlangan.

๐Ÿ“ Tavsif va kontent siyosati

Muallif resursni shaxsiy fikrni ifoda etish maydoni sifatida taโ€™riflaydi:
โ€œุจุณู… ุงู„ู„ู‡ ุงู„ุฑุญู…ู† ุงู„ุฑุญูŠู… ุงู„ู„ู‡ู… ุตู„ ุนู„ู‰ ู…ุญู…ุฏ ูˆุขู„ ู…ุญู…ุฏ ู…ุญุชูˆู‰ ุงู„ู‚ู†ุงุฉ: ุดุฑูˆุญุงุช ุตูŠุฏู„ุฉ ุนุถูˆูŠุฉ ู…ุฑุญู„ุฉ ุซุงู†ูŠุฉ ูƒูˆุฑุณ ุซุงู†ูŠ ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุซุงู„ุซุฉ ูƒูˆุฑุณ ุซุงู†ูŠ ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุฑุงุจุนุฉ ูƒูˆุฑุณ ุงูˆู„ ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุฑุงุจุนุฉ ูƒูˆุฑุณ ุซุงู†ูŠ ุนู„ุงุฌูŠุงุช ู…ุฑุญู„ุฉ ุฎุงู…ุณุฉ ู„ู„ุชูˆุงุตู„: @AronX2botโ€

Yuqori yangilanish chastotasi (oxirgi maโ€™lumot 29 Iyun, 2026 da olingan) sababli kanal doimo dolzarb va katta qamrovli boโ€˜lib qoladi. Analitika auditoriya kontent bilan faol hamkorlik qilishini, uni Tibbiyot toifasidagi muhim taโ€™sir nuqtasiga aylantirishini koโ€˜rsatadi.

13 339
Obunachilar
-1824 soatlar
+2847 kunlar
+19630 kunlar
Postlar arxiv
Leukemia โž” Therapy โž” Remission โž” Relapse ๐Ÿ”„
Leukemia โž” Therapy โž” Remission โž” Relapse ๐Ÿ”„

Relapse ALL Chemotherapy Allogeneic hematopoietic stem cell transplant (allo-HSCT)
Chemotherapy: ๐Ÿ”ธClofarabine โž” active in refractory acute leukemias ๐Ÿ”นBlinatumomab โž” targets CD19, for Ph negative relapsed or refractory ALL ๐Ÿ”ธInotuzumab ozogamicin โž” anti CD-22, used in relapsed and refractory B-ALL ๐Ÿ”นTisagenlecleucel โž” anti-CD19, used in patients with relapsed and refractory B-cell ALL
#Leukemia ๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ

Treatment of ALL 5 elements: Induction CNS directed Treatment Consolidation Reinduction Maintenance phase 1. Induction Therap
Treatment of ALL
5 elements: Induction CNS directed Treatment Consolidation Reinduction Maintenance phase
1. Induction Therapy: vincristine L- asparaginase steroid (prednisone or dexamethasone) ุงู„ Dexamethazone ู‡ูˆ ุงู„ู…ูุถู„ ู„ุงู† ูŠูƒุฏุฑ ูŠูˆุตู„ ู„ู„ CNS ู…ู…ฺฉู† ุจุงู„ู€ higher risk patient ู†ุถูŠู ุฏูˆุงุก ู…ู† ู…ุฌู…ูˆุนุฉ anthracycline
2. CNS prophylaxis: A. Intrathecal: Cytarabine MTX Steroid B. Systemic chemotherapy: Dexamethasone high-dose methotrexate ุจุงู„ุงุถุงูุฉ ุงู„ู‰ ุงู„ุฃุดุนุงุน craniospinal irradiation (XRT) in selected high-risk patients (T-cell ALL)
3. Consolidation High dose of chemotherapy 4. Reinduction A. Interim maintenance 2 months B. Delayed intensification for 3 months after remission ู†ูุณ ุงุฏูˆูŠุฉ ุงู„ induction ู†ุนูŠุฏู‡ุง ู…ู† ุฌุฏูŠุฏ 5. Maintenance phase oral methotrexate 6- mercaptopurine. 2-3 years with low dose
#Leukemia ๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ

ุตูˆุฑ ู…ุณุชุฎุฏู…ุฉ ููŠ ุงู„ุดุฑุญ
+1
ุตูˆุฑ ู…ุณุชุฎุฏู…ุฉ ููŠ ุงู„ุดุฑุญ

https://docs.google.com/forms/d/e/1FAIpQLSeV5Ee9LB-3h0xZcBA7hqOll-OlhqGlRzwDcwH5weT2mysiqA/viewform?usp=header ุงู„ุณู„ุงู… ุนู„ูŠูƒู… ุงุญู†ุง ู…ุฌู…ูˆุนุฉ ู…ู† ุทู„ุงุจ ู…ุฑุญู„ุฉ ุฎุงู…ุณู‡ ู…ู…ูƒู† ุชุณุงุนุฏูˆู†ู‡ ูˆุชู…ู„ูˆู† ุงู„ุงุณุชุจูŠุงู† ุจุฎุตูˆุต ุงู„ุฌุฑุนู‡ ุงู„ุณุงู…ู‡ ู„ู„ุจุฑุงุณูŠุชุงู…ูˆู„ (ูู‚ุท ุทู„ุงุจ ุงู„ุฎุงู…ุณ ูˆุงู„ุฎุฑูŠุฌูŠู†)

ู…ู…ูƒู† ู†ุดุฑ ู„ู‡ุฐ ุงู„ุงุณุชุจูŠุงู† ู…ุญุชุงุฌูŠู† ุนุฏุฏ ูƒุจูŠุฑ ๐Ÿ™ https://docs.google.com/forms/d/e/1FAIpQLScqN5unW538cop6DUFvF9oUiiU_ODA2rpwItFTWaP4iIx1DtQ/viewform?usp=publish-editor

ูˆู‡ุฐู†ูŠ ูู‚ุท ู…ุญุฐูˆูุงุช ู…ู† thyroid gland ู„ุงู† ู‡ู… ู…ู† ุดุฑุญุชู‡ุง ุฌุงู† ุงู„ู…ู†ู‡ุฌ ุงู„ุฌุฏูŠุฏ ุจุนุฏู‡ ู…ุง ู†ุงุฒู„ ุนู…ูˆู…ุง ู…ูˆ ุดูŠ ู…ุคุซุฑ ุจุณ ุญุชู‰ ูŠูƒูˆู† ุจุนู„ู…ูƒู… ุจุงู‚ูŠ ุง
+1
ูˆู‡ุฐู†ูŠ ูู‚ุท ู…ุญุฐูˆูุงุช ู…ู† thyroid gland ู„ุงู† ู‡ู… ู…ู† ุดุฑุญุชู‡ุง ุฌุงู† ุงู„ู…ู†ู‡ุฌ ุงู„ุฌุฏูŠุฏ ุจุนุฏู‡ ู…ุง ู†ุงุฒู„ ุนู…ูˆู…ุง ู…ูˆ ุดูŠ ู…ุคุซุฑ ุจุณ ุญุชู‰ ูŠูƒูˆู† ุจุนู„ู…ูƒู… ุจุงู‚ูŠ ุงู„ู…ูˆุงุถูŠุน ุงุฐุง ู†ุฒู„ุช ุงู„ู‡ุง ู…ู„ุงุฒู… ู…ุฑุชุจุฉ ุฑุญ ุชูƒูˆู† ู…ุนุชู…ุฏุฉ ุน ู…ู†ู‡ุฌ ูขู ูขูฆ ู…ู† ู…ูˆุถูˆุน ุงู„ูƒุงู†ุณุฑ ูˆุตุงุนุฏ

ุทู„ุงุจ ุงู„ุฎุงู…ุณ ู…ู† ุดุฑุญุช ู…ูˆุถูˆุน ุงู„ adrenal gland ุดุฑุญุชู‡ ุน ู…ู†ู‡ุฌ ุงู„ุนุงู… ู‚ุจู„ ู„ุง ูŠู†ุฒู„ ุงู„ู…ู†ู‡ุฌ ุงู„ุฌุฏูŠุฏ ู ู‡ุงูŠ ุงู„ู…ุนู„ูˆู…ุงุช ู…ุญุฐูˆูุฉ ู…ู† ุงู„ู…ู†ู‡ุฌ ุงู„ุฌุฏ
+4
ุทู„ุงุจ ุงู„ุฎุงู…ุณ ู…ู† ุดุฑุญุช ู…ูˆุถูˆุน ุงู„ adrenal gland ุดุฑุญุชู‡ ุน ู…ู†ู‡ุฌ ุงู„ุนุงู… ู‚ุจู„ ู„ุง ูŠู†ุฒู„ ุงู„ู…ู†ู‡ุฌ ุงู„ุฌุฏูŠุฏ ู ู‡ุงูŠ ุงู„ู…ุนู„ูˆู…ุงุช ู…ุญุฐูˆูุฉ ู…ู† ุงู„ู…ู†ู‡ุฌ ุงู„ุฌุฏูŠุฏ ุชุฌุงูˆุฒูˆู‡ุง ุจุงู„ุดุฑุญ

ุงู„ุณู„ุงู… ุนู„ูŠูƒู… ุจู„ุง ุฒุญู…ุฉ ู…ู…ูƒู† ุชู†ุดุฑู„ู†ุง ู‡ุฐุง ุงู„ุฅุณุชุจูŠุงู† ุจู‚ู†ุงุชูƒู… ูƒู„ุด ู…ุญุชุงุฌูŠู† ุนูŠู†ุงุช ู ูŠุง ุฑูŠุช ุชุณุงุนุฏูˆู†ุง ุŒ ูˆ ุงู„ู„ู‡ ูŠุฌุนู„ู‡ุง ุจู…ูŠุฒุงู† ุญุณู†ุงุชูƒู… ุฌู…ูŠุนุงู‹ https://forms.gle/MC4K1X7HsvxCE6RW8

ู‚ู†ุงุฉ ุฏูƒุชูˆุฑ ุนุจุงุณ ุงู† ุดุงุก ุงู„ู„ู‡ ุชููŠุฏูƒู… ุงู„ุงุฏูุงู†ุณ

๐Ÿ›‘ู‚ู†ุงุฉ ุฎุงุตุฉ ุจุดุฑุญ ู…ุงุฏุฉ ุงู„ุฃุฏูุงู†ุณ ู„ู„ู…ุฑุญู„ุฉ5 ูƒู„ูŠุฉ ุงู„ุตูŠุฏู„ุฉ ุจุงู„ุฅุนุชู…ุงุฏ ุนู„ู‰ ุงู„ู…ุตุฏุฑ ุงู„ูˆุฒุงุฑูŠ ู„ุณู†ุฉ 2026โœ… ๐Ÿ›‘ุดุฑุญ ุงู„ุตูŠุฏู„ุงู†ูŠ ุนุจุงุณ ุญูŠุฏุฑ ู‡ู„ุงู„โœ… ุฎุฑูŠุฌ ูƒู„ูŠุฉ ุงู„ุตูŠุฏู„ุฉ(ุฌุงู…ุนุฉ ุงู„ู‚ุงุฏุณูŠุฉ) ู…ู† ุงู„ุฃูˆุงุฆู„ ุนู„ู‰ ุงู„ูƒู„ูŠุฉโœ… ๐Ÿ›‘ุงู„ุดุฑุญ ุนู„ู‰ ุงู„ู…ุตุฏุฑ ุงู„ูˆุฒุงุฑูŠ ุงู„ู…ูˆุญุฏ ูˆุนู„ู‰ ุดูƒู„ ูุฏูŠูˆุงุช ุจุงู„ูŠูˆุชูŠูˆุจ+ ุญู„ ุฃุณุฃู„ุฉ ูˆู…ู„ุฎุตุงุช ุจู‚ู†ุงุฉ ุงู„ุชู„ูŠโœ… ๐Ÿ›‘ุฑุงุจุท ุงู„ู‚ู†ุงุฉ ุจุงู„ุชู„ูŠ/ t.me/Ph_Abbas_Hilal โœ… ๐Ÿ›‘ู…ุนุฑู ุงู„ุชู„ูŠ/ @ph6ab โœ… ๐Ÿ›‘ุฑุงุจุท ุดุฑุญ ุฃูˆู„ ูุฏูŠูˆ ุนู„ู‰ ุงู„ูŠูˆุชูŠูˆุจ/ https://youtu.be/BLwWJx2vZqc?si=p7KNoOqQtvLAE4o3 โœ